Investors & Media

Press Releases

 
Press Releases
Date Title and Summary View
Sep 29, 2014 WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics, today announced that Douglas M. Fambrough, PhD, President and CEO, will present at three upcoming conferences, including the 2014 Leerink Rare Disease Roundtable, Berns...
Sep 15, 2014 WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics, announced today the appointment of Bruce Peacock to its board of directors and audit committee. Mr. Peacock currently serves as chief financial and business officer at Ophthotec...
Sep 2, 2014 Attending the FBR Inaugural Healthcare Conference WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics, today announced that Douglas M. Fambrough, PhD, President and CEO, will present at the 2014 ...
Aug 21, 2014 US PTO 8,809,515 "515" Provides Opportunity to Design, Optimize and Target Dicerna's DsiRNAs in Drug Development WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics, today announced a series of recently issue...
Aug 7, 2014 -Management to Host Conference Call Today at 4:30 pm ET- WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics targeting genetically defined oncology and inherited rare diseases, today announced opera...
Jul 25, 2014 WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, today announced that the Company will release its second-quarter 2014 financial results after market close on Thursday, August 7. Management w...
Jul 11, 2014 WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, today announced that the Company will ring the NASDAQ Stock Market closing bell on Tuesday, July 15, 2014. "Dicerna has achieved significant milestones in the f...
Jun 30, 2014 DCR-PH1 Uses Proprietary Dicer Substrate RNAi Technology to Inhibit Enzyme Implicated in Rare Liver Disorder WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics, today announced the presentati...
Jun 19, 2014 WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, today announced that Douglas M. Fambrough, PhD, the Company's President and CEO, will present at the 9th Annual JMP Securities Healthcare Conference on June 24 2014, at 1:00 PM...
May 23, 2014 WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, today announced that Douglas M. Fambrough, PhD, President and CEO, will present at Jefferies 2014 Global Healthcare Conference on June 2, 2014, at 10:00am ET in New York, NY. I...
May 19, 2014 Watertown, MA, May 19, 2014 - Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, today announced the Company received the "Deal of the Year- Healthcare" award at the 2014 NEVY Awards, a celebration of the most innovative and exciting companies in Boston hosted by the New England Venture...
May 13, 2014 - DCR-MYC Becomes First Dicer Substrate RNA Interference Drug Candidate to Enter Clinical Trials - - Management to Host Conference Call at 4:30 PM ET - WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RN...
May 8, 2014 WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, will report its first quarter 2014 financial results on May 13, 2014. Dicerna will host a conference call and live audio webcast on May 13, 2014, at 4:30 p.m. (ET) to ...
Apr 18, 2014 WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, today announced that it granted stock options to Pankaj Bhargava, M.D., the Company's chief medical officer, on April 16, 2014, including a stock option to purchase 246,406 ...
Apr 16, 2014 -DCR-MYC is the First Dicer Substrate RNA Interference Candidate to Advance into Clinical Testing- WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, today announced the initiation of a Phase 1 do...
Apr 2, 2014 WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, today announced the appointment of Pankaj Bhargava, M.D., as Chief Medical Officer. Dr. Bhargava brings to Dicerna more than 15 years of experience in oncology drug development...
Mar 27, 2014 -DCR-M1711 to Enter Phase 1 Clinical Trials in First Half of 2014- -Management to Host Conference Call at 4:30 PM ET- WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, today provided a cor...
Mar 25, 2014 WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, today announced that Douglas M. Fambrough, PhD, the Company's President and CEO, is scheduled to present at the 21st Annual Future Leaders in the Biotech Industry conf...
Mar 24, 2014 WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, will report its fourth quarter 2013 financial results on March 27, 2014. Dicerna will host a conference call and live audio webcast on March 27, 2014 at 4:30 p.m. (ET) to ...
Mar 6, 2014 WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics, today announced that members of the management team will present at two upcoming conferences: Bernstein Emerging Biotech Conference 2014, Snowbird, U...
Feb 24, 2014 WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics, today announced that Bob D Brown, PhD, the Company's Chief Scientific Officer and SVP, is scheduled to participate in the 2014 AsiaTIDES Conference being held in Tokyo, Japan Fe...
Feb 7, 2014 WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, today announced that Douglas M. Fambrough, PhD, the Company's President and CEO, is scheduled to present at the 2014 Leerink Global Healthcare Conference on Thursday, February ...
Feb 5, 2014 WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics, today announced its participation in a panel discussion on RNAi therapeutics at the 16th Annual BIO CEO & Investor Conference. Douglas M. Fambrough, PhD, the company's President...
Feb 4, 2014 WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) today announced the closing of its initial public offering of 6,900,000 shares of common stock, including 900,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shar...
Jan 29, 2014 Watertown, MA, January 29, 2014 - Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) today announced the pricing of its initial public offering of 6,000,000 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts. In addition, Dicerna has granted the underwriters a 30-day option to purchase up to an additional...
Jan 4, 2014
PDF
Add to Briefcase
Oct 9, 2013
PDF
Add to Briefcase
Aug 1, 2013
PDF
Add to Briefcase
Jul 1, 2013
PDF
Add to Briefcase
Apr 2, 2013
PDF
Add to Briefcase
Mar 19, 2013
PDF
Add to Briefcase
Jan 3, 2013
PDF
Add to Briefcase
Oct 24, 2012
PDF
Add to Briefcase
Sep 17, 2012
PDF
Add to Briefcase
Aug 8, 2012
PDF
Add to Briefcase
Jan 4, 2012
PDF
Add to Briefcase
Dec 15, 2011
PDF
Add to Briefcase
Nov 1, 2011
PDF
Add to Briefcase
Sep 6, 2011
PDF
Add to Briefcase
Jun 8, 2011
PDF
Add to Briefcase
Feb 28, 2011
PDF
Add to Briefcase
Dec 7, 2010
PDF
Add to Briefcase
Nov 3, 2010
PDF
Add to Briefcase
Nov 2, 2010
PDF
Add to Briefcase
Oct 21, 2010
PDF
Add to Briefcase
Sep 30, 2010
PDF
Add to Briefcase
Sep 15, 2010
PDF
Add to Briefcase
Sep 9, 2010
PDF
Add to Briefcase
Aug 11, 2010
PDF
Add to Briefcase
Jun 23, 2010
PDF
Add to Briefcase
Jun 6, 2010
PDF
Add to Briefcase
May 6, 2010
PDF
Add to Briefcase
Mar 30, 2010
PDF
Add to Briefcase
Sep 21, 2009
PDF
Add to Briefcase
Sep 2, 2009
PDF
Add to Briefcase
Aug 3, 2009
PDF
Add to Briefcase
Jul 21, 2009
PDF
Add to Briefcase
Jul 8, 2009
PDF
Add to Briefcase
Jun 4, 2009
PDF
Add to Briefcase
May 13, 2009
PDF
Add to Briefcase
Apr 27, 2009
PDF
Add to Briefcase
Mar 24, 2009
PDF
Add to Briefcase
Mar 18, 2009
PDF
Add to Briefcase
Nov 26, 2008
PDF
Add to Briefcase
Nov 20, 2008
PDF
Add to Briefcase
Nov 17, 2008
PDF
Add to Briefcase
Oct 22, 2008
PDF
Add to Briefcase
Oct 16, 2008
PDF
Add to Briefcase
Oct 15, 2008
PDF
Add to Briefcase
Oct 1, 2008
PDF
Add to Briefcase
Jul 15, 2008
PDF
Add to Briefcase
Jun 9, 2008
PDF
Add to Briefcase
Jan 29, 2008
PDF
Add to Briefcase
Nov 14, 2007
PDF
Add to Briefcase
Page:
1
Add to Briefcase = add release to Briefcase